News

March 1, 2019

Specific Gene Mutations Predict Success of Immunotherapy in Glioblastoma Patients, Study Reports

News

Testing for specific gene mutations may help predict the patients with glioblastoma who will respond to immunotherapy, according to new research. The findings also suggest a therapeutic target that could ... Read more

February 27, 2019

FDA Approves Keytruda for Melanoma Patients After Tumor Resection

News

The U.S. Food and Drug Administration has approved the use of Keytruda (pembrolizumab) as a treatment for melanoma patients with stage 3 disease — cancer cells have spread to the lymph ... Read more

February 26, 2019

First Mesothelioma Patient Dosed in Phase 1 Trial of Curis’ CA-170

News

The Phase 1 trial evaluating Curis‘ investigational immunotherapy CA-170 for advanced cancers has dosed its first mesothelioma patient, the company announced. The trial (NCT02812875), currently enrolling participants, will test the therapy in adults ... Read more

February 22, 2019

Keytruda Better Than Chemotherapy for Untreated Advanced Merkel Cell Carcinomas, Phase 2 Trial Suggests

News

Patients with an aggressive kind of skin cancer called Merkel cell carcinoma appear to have better responses and live longer when given the PD-1 inhibitor Keytruda (pembrolizumab), compared to previous ... Read more

February 20, 2019

FDA Grants Priority Review to Keytruda-Inlyta Combo for Untreated, Advanced Kidney Cancer Patients

News

The U.S. Food and Drug Administration has granted priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the initial treatment of advanced ... Read more

February 19, 2019

European Panel Favors Approval of Keytruda-Chemo Combo as First-line Therapy for NSCLC

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda (pembrolizumab) in combination with chemotherapy for the initial treatment ... Read more

February 15, 2019December 16, 2020

EMD Serono, GSK Partner to Advance in Trials New Class of Immunotherapy Against Advanced Cancers

News

Merck KGaA and GlaxoSmithKline (GSK) are working together to develop and commercialize the immunotherapy candidate M7824 (bintrafusp alfa) as a potential treatment for multiple, difficult-to-treat types of cancer. M7824 is being ... Read more

February 13, 2019

Eureka Plans US Trial Testing ET140202 T-cell Therapy in Liver Cancer Patients

News

Eureka Therapeutics is planning a Phase 1/2 clinical trial in the United States to explore the safety and effectiveness of its investigational T-cell therapy ET140202 in patients with advanced hepatocellular ... Read more

February 12, 2019February 12, 2019

Bavencio Shows Promise in Phase 1 Trial of Heavily Treated Malignant Mesothelioma Patients

News

Immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients, according to a Phase 1 clinical trial. The treatment — jointly ... Read more

February 8, 2019February 8, 2019

GE Healthcare, Vanderbilt University Medical Center to Develop Apps that Predict Immunotherapy Responses

News

GE Healthcare and Vanderbilt University Medical Center (VUMC) have established a five-year partnership aimed at developing new diagnostic tools to predict how an immunotherapy will work — as far as ... Read more